Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global Transformation? Sun Pharma Names Former Teva CEO Israel Makov As Chairman

This article was originally published in PharmAsia News

Executive Summary

Experts say the Indian pharma’s strategy may be to drive high growth in RoW markets and enable a transition to professional management.

You may also be interested in...

Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma

MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India

Former Teva CEO Israel Makov On Hurdles For Innovative Drug Companies Entering Generics Space: An Interview With PharmAsia News

Israel Makov's four years as generic giant Teva's chief executive officer, until 2007, were the most outstanding for the company as it took up patent challenges on billion dollar brands while making deep inroads into the innovation domain with its multiple sclerosis brand Copaxone. Makov now heads medical devices company Given Imaging, but is still very closely following movements in the global generic drug industry. Makov met with PharmAsia News' India bureau chief on the sidelines of the recent BioPharma Asia conference in Singapore to speak about his past experiences and what lies ahead for the industry - from generic chemical drugs to biosimilars.

Teva Could Modify Its "Authorized" Generic Policy Following Ivax Acquisition

Deal worth $7.4 bil. brings Teva a new subsidiary that participates in the authorized generic market.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts